2024-06-25T14:40:13-05:00 2023-12-31 042571780 AAFCPAS INC 50 WASHINGTON STREET WESTBOROUGH MA 01581 990 2023-01-01 043462719 ALS THERAPY DEVELOPMENT FOUNDATION INC ALST 6174417200 480 ARSENAL STREET 201 WATERTOWN MA 02472 DR FERNANDO VIEIRA CEO/CSO 6174417200 2024-06-24 1 DR FERNANDO VIEIRA XXX-XX-XXXX 1 THOMAS F MULDOON CPA P01561688 5083669100 2024-06-24 2 AAL1 IAL1 2023 2023-04-26 12:10:37Z ALS THERAPY DEVELOPMENT INSTITUTE DR FERNANDO VIEIRA 480 ARSENAL STREET 201 WATERTOWN MA 02472 12415651 0 X WWW.ALS.NET X 1999 MA WE ARE COMMITTED TO CREATING AND LEADING A TRANSPARENT COLLABORATIVE RESEARCH PROCESS THAT INVOLVES ALS PATIENTS TODAY AND HONORS THOSE WHOSE JOURNEY WITH THIS DISEASE HAS ENDED. WE ARE GUIDED BY PASSION, LOVE AND THE SPIRIT OF ENTREPRENEURSHIP UPON WHICH WE WERE FOUNDED. 18 17 63 500 0 0 9817402 10029574 636927 657980 66813 363770 843027 507158 11364169 11558482 0 0 0 0 4486981 4968144 0 27160 568158 5342558 6165289 9829539 11160593 1534630 397889 21051525 20012651 5823044 5001719 15228481 15010932 OUR MISSION IS TO IDENTIFY VIABLE TARGETS FOR THERAPY DEVELOPMENT AND EXPEDITIOUSLY MANAGE THE CREATION OF THOSE TREATMENTS THAT WILL ARREST THE SUFFERING OF TODAY'S ALS PATIENTS. 0 0 9880001 661561 ALS TDI COMBINES THE PASSION AND DEDICATION OF A NONPROFIT ORGANIZATION WITH THE ENTREPRENEURIAL AND SCIENTIFIC SPIRIT OF A BIOTECHNOLOGY COMPANY. OUR LABORATORY IS THE LEADING DRUG DISCOVERY PROGRAM FOR ALS, AND IT BRIDGES A CRITICAL RESEARCH GAP. OUR IN-HOUSE EXPERTISE TRANSLATES RESEARCH INTO POTENTIAL DRUG CANDIDATES BY SCREENING DRUGS IN THE SOD1 MOUSE MODEL OF ALS. OUR SCIENTIFIC COLLABORATIONS ARE DESIGNED TO BRING THE MOST PROMISING LEADS CLOSER TO PATIENT USE. WE SHARE EMERGING KNOWLEDGE ON THE DISEASE WITH PATIENTS, PHYSICIANS, AND RESEARCHERS AS QUICKLY AND COMPREHENSIVELY AS POSSIBLE. EVERY DECISION IS MADE IN THE INTEREST OF FINDING EFFECTIVE TREATMENTS FOR PEOPLE LIVING WITH ALS. OUR UNIQUE APPROACH ACCELERATES DRUG DEVELOPMENT FOR ALS. 9880001 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 40 0 1 63 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 18 17 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX SD UT VT VA WA WV WY WI X X INSOURCE SERVICES INC 7812351490 148 LINDEN STREET WELLESLEY MA 02482 FERNANDO VIEIRA CEO AND CSO 40.00 X X 320000 0 20011 ALAN GILL VP OF RESEARCH 40.00 X 182421 0 13214 CAROL HAMILTON VP OF DEVELOPMENT 40.00 X 165724 0 8146 THEO HATZIPETROS DIRECTOR OF PHARMACOLOGY 40.00 X 150899 0 20236 KYLE R DENTON DIRECTOR, CELL BIOLOGY 40.00 X 150194 0 8434 KENNETH THOMPSON VP OF FACILITY OPERATION 40.00 X 129202 0 19011 LYNNE NIETO CHAIRMAN (AS OF 5/2023) 2.50 X X 0 0 0 AUGIE NIETO CHAIRMAN (UNTIL 2/2023) 2.50 X X 0 0 0 STEVEN PERRIN PHD VICE CHAIR 2.50 X X 0 0 0 THEODORE REICH JD CPA TREASURER AND BOARD MEMBER 2.50 X X 0 0 0 DR STANLEY H APPEL MD BOARD MEMBER 2.50 X 0 0 0 ALEXANDER CAPPELLO BOARD MEMBER 2.50 X 0 0 0 DR SPIROS JAMAS SCD BOARD MEMBER 2.50 X 0 0 0 JAMES ALLEN HEYWOOD BOARD MEMBER 2.50 X 0 0 0 JOHN B HEYWOOD PHD SCD BOARD MEMBER 2.50 X 0 0 0 ROB RODIN BOARD MEMBER 2.50 X 0 0 0 PAUL SALLABERRY BOARD MEMBER 2.50 X 0 0 0 ROBERT SEPUCHA BOARD MEMBER 2.50 X 0 0 0 JENNY DWYER BOARD MEMBER 2.50 X 0 0 0 MIKE SMITH BOARD MEMBER 2.50 X 0 0 0 JULIE SWAN BOARD MEMBER 2.50 X 0 0 0 KENT JACKSON BRANSFORD MD BOARD MEMBER 2.50 X 0 0 0 ANDREW NIBLOCK BOARD MEMBER 2.50 X 0 0 0 TOM ENGELLENNER BOARD MEMBER 2.50 X 0 0 0 1098440 0 89052 9 0 1 0 INSOURCE SERVICES INC PO BOX 427 NEWTON UPPER FALLS MA 02464 FINANCE, HR & IT 556808 UNITE GENOMICS INC 951 MARINERS ISLAND BLVD SUITE 300 SAN MATEO CA 94404 RESEARCH CONSULTANT 116000 SOMALOGIC OPERATING CO INC 2945 WILDERNESS PL BOULDER CO 80301 RESEARCH CONSULTANT 110000 3 5194033 4835541 260590 10029574 PHARMACEUTICAL CONTRACTS 541700 657980 657980 657980 363770 363770 1360746 5194033 857169 503577 503577 CONTRACTED SERVICES 541900 3581 3581 3581 11558482 661561 0 867347 340011 272009 34001 34001 3753298 3356266 277783 119249 38088 33249 3197 1642 528763 466672 38299 23792 307984 273026 23422 11536 103456 103456 51334 51334 27160 27160 639135 569055 41140 28940 61856 217 61639 149050 118174 6947 23929 608631 525056 8019 75556 1673353 1588308 67756 17289 5638 5638 119580 74628 10 44942 14228 14228 186568 174165 9704 2699 107539 95085 8329 4125 TESTING AND LAB EXPENSE 2174287 2174287 BANK AND CREDIT CARD PR 82017 2774 79243 CREDIT LOSS 71974 71974 MISCELLANEOUS 61892 29529 31437 926 54751 38435 4826 11490 11160593 9880001 712434 568158 3467200 282198 7748460 6415329 389388 455824 1053475 97420 174487 297565 3159320 2766318 192136 393002 3231414 7976815 775666 875678 4019299 3218820 21051525 20012651 532001 426183 94575 153454 5196468 4422082 5823044 5001719 X 14928481 14810932 300000 200000 15228481 15010932 21051525 20012651 397889 -615438 0 X X 0 1 X 1 0 X 11823260 8062216 10588016 9817402 10029574 50320468 11823260 8062216 10588016 9817402 10029574 50320468 248856 50071612 50014 17725 8195 66813 363770 506517 279636 90017 3794 103162 3581 480190 51307175 2599141 0.97590 0.92000 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 62470 54699 7771 3096850 2711619 385231 393002 RIGHT-OF-USE ASSETS - FINANCE 303086 RIGHT-OF-USE ASSETS - OPERATING 2915734 3218820 FINANCE LEASE LIABILITIES 318553 OPERATING LEASE LIABILITY 4103529 4422082 X 10946389 -615438 3345 -612093 11558482 0 11558482 11163938 3345 3345 11160593 0 11160593 PART X, LINE 2: ALS TDI ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH ASC TOPIC, INCOME TAXES. THIS STANDARD CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS AND PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE FINANCIAL STATEMENTS REGARDING A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. ALS TDI HAS DETERMINED THAT THERE ARE NO UNCERTAIN TAX POSITIONS WHICH QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THEIR FINANCIAL STATEMENTS AT DECEMBER 31, 2023. THE INFORMATIONAL RETURNS OF ALS TDI ARE SUBJECT TO EXAMINATION BY THE FEDERAL AND STATE JURISDICTIONS AND GENERALLY REMAIN OPEN FOR THE MOST RECENT THREE YEARS. X X X 1 REBECCA WETZEL 13 N SUMMIT AVE CHATHAM NJ 07928 HOSTING EVENTS, AND SOLICITING MAJOR DONORS, FROM HER PERSON 0 62694 27160 35534 62694 27160 35534 AZ CA FL HI IL KY MI MS MT NH NJ NM ND OK SC UT VA WV WY WA WHITE COAT AFFAIR 615438 485730 129708 32827 128959 71012 TRI-STATE TREK 634809 620459 14350 94158 13184 195 62748 350 5304532 4087844 1216688 348738 40999 4496 59853 6554779 5194033 1360746 475723 183142 4691 193613 857169 503577 X X X X 0 0 0 0 0 0 0 0 0 FERNANDO VIEIRA CEO AND CSO 320000 0 0 0 0 0 0 0 20011 0 340011 0 0 0 ALAN GILL VP OF RESEARCH 182421 0 0 0 0 0 1000 0 12214 0 195635 0 0 0 CAROL HAMILTON VP OF DEVELOPMENT 165724 0 0 0 0 0 1000 0 7146 0 173870 0 0 0 THEO HATZIPETROS DIRECTOR OF PHARMACOLOGY 150899 0 0 0 0 0 1000 0 19236 0 171135 0 0 0 KYLE R DENTON DIRECTOR, CELL BIOLOGY 150194 0 0 0 0 0 1000 0 7434 0 158628 0 0 0 CLARE REICH EMPLOYEE 63880 DAUGHTER OF A BOARD MEMBER; WAGES PAID AS AN EMPLOYEE 0 X 7 260590 FMV 0 1 0 FORM 990, PART VI, SECTION A, LINE 2 JAMES HEYWOOD, BOARD MEMBER, IS THE SON OF JOHN HEYWOOD, MEMBER OF THE BOARD OF DIRECTORS. ADDITIONALLY, LYNNE NIETO AND KENT BRANSFORD, BOARD MEMBERS, ARE RELATED. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS REVIEWED BY THE CHIEF FINANCIAL OFFICER AND THEN APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C ALS TDI HAS A WRITTEN CONFLICT OF INEREST POLICY WHICH REQUIRES ANNUAL SIGNOFFS BY OFFICERS, DIRECTORS AND KEY EMPLOYEES. FORM 990, PART VI, SECTION B, LINE 15 THE PROCESS TO DETERMINE THE COMPENSATION OF THE PRESIDENT CONSISTS OF EVALUATING COMPARABLE DATA FOR FUNCTIONALLY SIMILAR POSITIONS AT SIMILAR ORGANIZATIONS, ALONG WITH THE REVIEW AND APPROVAL BY THE EXECUTIVE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WHICH IS COMPRISED OF INDEPENDENT MEMBERS. FORM 990, PART VI, SECTION B, LINE 15B: THE PROCESS TO ESTABLISH COMPENSATION OF OTHER OFFICERS AND KEY EMPLOYEES IS COMPLETED ON AN ANNUAL BASIS BY EVALUATING COMPARABLE DATA FOR FUNCTIONALLY SIMILAR POSITIONS AT SIMILAR ORGANIZATIONS, PRESENTING RECOMMENDATIONS TO THE EXECUTIVE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WHICH IS COMPRISED OF INDEPENDENT MEMBERS AND DOCUMENTING SUCH DISCUSSIONS IN THE BOARD MINUTES. FORM 990, PART VI, SECTION C, LINE 18 ALS TDI'S FORM 990 IS AVAILABLE FOR PUBLIC INSPECTION ON ALS TDI'S WEBSITE AND AT WWW.GUIDESTAR.COM. ALS TDI'S FORM 1023 IS AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE MADE AVAILABLE ON ALS TDI'S WEBSITE AND ARE AVAILABLE BY MAIL UPON REQUEST. GOVERNING DOCUMENTS AND ALS TDI'S CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C: DURING 2023, THE ORGANIZATION DID NOT CHANGE THE WAY IN WHICH ITS COMMITTEE ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT, ITS FINANCIAL STATEMENTS, AND SELECTION OF AN INDEPENDENT ACCOUNTANT.